Create scientific presentation for 10 min in english from this article

Created using ChatSlide

The SELECT Heart Failure Analysis highlights the significance of obesity in cardiovascular and heart failure risks, as detailed in Deanfield et al. in *Lancet* 2024. The trial involved 17,604 adults across 41 countries, comparing semaglutide 2.4 mg weekly to placebo in patients with a BMI of 27 or higher and a history of ASCVD. Results showed a reduction in cardiovascular death and all-cause mortality, with benefits evident within six months, emphasizing the need for clinical interpretation...